HealthEquity: A Custodial Compounder Trading Near Fair Value

The Quarter in Context

HealthEquity, an HSA custodian and consumer-directed benefits administrator, posted second-quarter revenue of $350.7 million, up 7.6% year over year, with gross margin near 73.5% and operating income of $98.7 million. Net income reached $65.6 million and diluted EPS of $0.78 grew 14.7%, helped by ongoing share repurchases that shrunk diluted weighted-average shares by about 4.3%. The most striking feature is the cash profile: operating cash flow of $136.2 million against capital expenditure of only $1.0 million, the latter stated on a cumulative six-month basis and reported as $978 thousand in the package. Stock-based compensation of $22.2 million in the quarter is a real cost but is non-cash. Long-term debt of $931.1 million against $256.0 million of cash means the balance sheet is net-debt rather than net-cash. The quarter therefore looks like a maturing compounder: steady revenue growth, very high cash conversion, deliberate return of capital, but with leverage still sitting on top of the equity story.

Business Model and Profit Engine

HealthEquity earns revenue from three streams disclosed in the income statement: service revenue, custodial revenue and interchange revenue. Service revenue, $124.4 million in the quarter, is paid primarily by employers (Clients), benefits brokers and Network Partners, plus members themselves, for administering HSAs, FSAs, HRAs, COBRA and commuter benefits, and for the in-house investment platform. Custodial revenue of $175.9 million is largely the spread between what the company's insurance and Depository Partners pay on HSA cash balances (held in custody on behalf of members) and what is credited back to those members; the company administered $37.9 billion of HSA Assets at quarter end. Interchange revenue of $50.4 million comes from payment-card transactions on member accounts. No single customer accounted for more than 10% of revenue in the six-month period, which reduces customer-concentration risk but leaves the model exposed to systemic HSA adoption, high-deductible health-plan enrollment and the prevailing interest-rate environment that drives custodial spreads.

The revenue mix translates cleanly into profit. Cost of revenue was $92.8 million against $350.7 million of revenue, producing a gross profit of $258.0 million and a 73.5% gross margin. Operating expenses of $159.3 million included $52.8 million of amortization of acquired intangible assets for the six months, so the cost base is heavily technology, amortization and personnel rather than physical goods; the company does not carry meaningful inventory. Operating income of $98.7 million in the quarter implies a 28.1% operating margin, well above what the capital intensity would suggest for a financial administrator. Capital intensity is low: cumulative six-month cash capex of $32.1 million against six-month operating cash flow of $233.7 million, with the $30.7 million of capitalized software development costs included inside that total. Working capital is light, with accounts receivable of $122.2 million against quarterly revenue of $350.7 million. The cash engine is essentially the spread on float, plus recurring fees, plus interchange, less fixed technology and amortization costs; observable risks to that engine are a sustained drop in short-term rates, which would compress custodial revenue, and any regulatory change that meaningfully weakens the HSA tax-advantaged status.

Earnings Quality and Cash Conversion

Where the issuer reports cash flow and capital expenditure cumulatively, the standalone-quarter cash-flow figures are derived by subtracting the preceding cumulative filing. They are calculations from SEC facts rather than separately reported quarterly line items. On a trailing-twelve-month basis, operating cash flow was $490.2 million against net income of $236.5 million, so cash earnings are roughly 2.07 times reported accounting earnings; that gap is largely stock-based compensation (TTM of $81.3 million), deferred taxes, and amortization of acquired intangibles. The standalone quarter figure of $136.2 million of operating cash flow was derived from cumulative six-month filings by subtracting the prior six-month cumulative result, so it is an author calculation built from SEC facts rather than a reported quarterly line item. That derived quarterly cash number still exceeds quarterly net income of $65.6 million, indicating that quarterly cash earnings are even higher than the accounting suggests once the non-cash amortization and stock-based compensation adjustments are kept in view. The earnings-quality picture is favorable in the sense that revenue is largely recurring, customer churn appears limited, and bad-debt exposure is small (allowance for doubtful accounts of $1.1 million against $122.2 million of receivables). The weakness is the non-cash stock-based compensation of $81.3 million TTM, which is a real dilution cost even though it does not consume cash.

Business Quality, Moat, and Industry Position

On the available evidence, the company is best described as an important participant, not a demonstrated core supply-chain bottleneck. This classification describes strategic position only; it is not independent proof of a moat or valuation upside. HealthEquity is described in its own filings as the largest HSA provider by account count and the second-largest by HSA Assets, with 20% market share of HSA Assets as of June 2025, up from 4% in 2010, and 17.8 million total accounts across HSAs and complementary consumer-directed benefits as of January 31, 2026. The moat is regulatory and structural rather than purely technological. Becoming an IRS-approved non-bank custodian is itself a qualification barrier; once established, the company sits inside a tax-advantaged account relationship that is portable across jobs and difficult to dislodge. The reported source of differentiation is a network of more than 200 integrated Network Partners (health plans, benefits administrators, retirement plan recordkeepers) plus direct sales through benefits brokers, which together create high switching costs for employers and stickiness for members. Custodial revenue tied to $37.9 billion of HSA Assets is a function of interest rates, but the company has built an Enhanced Rates offering and diversified partners with three-to-five-year contract terms to reduce short-term rate exposure. The bottleneck score is therefore meaningful but not absolute: substitution to a competitor requires employer re-enrollment, partner reintegration and member re-banking, and the custodian has pricing power on the float spread within contractual bands.

Management and Capital Allocation

Management's stated capital allocation policy is observable through the numbers: buybacks dominate, dividends are absent (no dividend line appears in the filing facts), and debt is being gradually paid down. During the first half of fiscal 2027 the company repurchased $231.1 million of stock and prepaid $26.9 million of revolver principal, while cash declined by $62.9 million to $256.0 million. Diluted shares fell from 87.7 million to 84.0 million over the trailing year, a clear signal of disciplined buyback execution at prices below where the stock currently trades on average. Acquisitions are part of the playbook; the $425.0 million BenefitWallet HSA portfolio acquisition in fiscal 2025, financed in part with revolver borrowings, added roughly 616,000 HSAs and $2.7 billion of HSA Assets. The capital-allocation lens is therefore: (1) tuck-in HSA portfolio acquisitions when available, (2) aggressive buybacks when shares trade below intrinsic value, (3) modest debt paydown, and (4) no dividend. This is owner-style capital allocation, supported by $22.2 million of quarterly stock-based compensation that is dilutive but smaller than the buyback program.

Valuation and What the Market Already Expects

At the August 27, 2026 market snapshot, HQY closed at $93.44 against a dated market capitalization of $7.812 billion. The balance-sheet snapshot as of July 31, 2026 carries $931.1 million of long-term debt (principal of $935.0 million less $3.9 million of unamortized discount and issuance costs) and $256.0 million of cash, implying a net-debt position of roughly $675.1 million and an enterprise value of approximately $8.49 billion. Trailing-twelve-month free cash flow, calculated as TTM operating cash flow of $490.2 million less TTM capex of $2.45 million, is approximately $487.7 million, a roughly 6.2% free-cash-flow yield on the dated market cap. Revenue grew 7.6% year over year in the latest quarter and TTM operating cash flow grew only 0.2%, which means the market is paying for a high-quality but slower-compounding stream of cash; the reverse-DCF implied growth embedded in the dated market cap is approximately 3.2% per year. The dated price therefore sits inside the band where the market is asking for modest but not aggressive compounding, and the dated market capitalization is within 20% of the base-scenario fair value of the deterministic calculation, which permits a fairly-valued conclusion without naming any specific fair value figure here.

Ten-Year Cash Flow to Fair Market Value

The starting free cash flow is the normalized SEC cash-flow proxy, while every growth rate, discount rate and terminal rate below is an explicit editorial assumption rather than company guidance. Each annual cash flow is forecast and discounted separately; terminal value is year-ten free cash flow multiplied by one plus terminal growth, divided by discount rate minus terminal growth, and then discounted back ten years. Fair market capitalization equals that explicit ten-year present value plus discounted terminal value and a same-date balance-sheet adjustment when available. If current cash and debt facts do not share one report date, the table shows the adjustment as unavailable and conservatively applies zero. The share count is derived from the dated market capitalization and share price so US shares and foreign ADRs use a consistent traded-security denominator.

In the reverse-DCF, holding the 9% discount rate and 3% terminal growth fixed, and solving only for one constant growth rate rather than using the base-case growth path, the current market capitalization implies roughly 3.2% annual free cash flow growth for ten years. This is a sensitivity framework, not a price target: the terminal-value share shows how strongly each result depends on assumptions beyond the explicit forecast. Negative margin of safety means the current market capitalization exceeds the scenario value.

Five Value-Investing Lenses

Benjamin Graham Lens

The Graham discipline asks whether a security is an investment rather than a speculation and whether the balance sheet supports the price. HealthEquity carries $931.1 million of long-term debt against $256.0 million of cash, so the equity is not net-cash but it is also not over-levered relative to $490.2 million of TTM operating cash flow. Stockholders' equity of $1.99 billion and goodwill of $1.65 billion dominate the balance sheet, but goodwill is essentially an HSA-custodian franchise that has demonstrated durable revenue and cash generation. Working capital is positive and current liabilities are small at $153.8 million, so near-term liquidity is not strained. The dated price at 6.2% trailing free-cash-flow yield is not a deep bargain; it is closer to a fair-quality price than a margin-of-safety price. Graham would call this a security worth watching rather than a bargain candidate.

Benjamin Franklin Lens

The Franklin lens is about capital discipline and opportunity cost. HealthEquity spent $231.1 million on buybacks in the first half of the fiscal year, prepaid $26.9 million of revolver debt, and held cash down at $256.0 million, while generating $233.7 million of operating cash flow in the same period. The company pays no dividend, which means every dollar of excess cash is being directed either to repurchases at prices below the current quote on average or to deleveraging, both of which compound per-share value over time. Capitalized software development costs of $30.7 million out of $32.1 million of total capex imply the reinvestment dollar is going into proprietary technology rather than physical assets, which is the right place for a software-platform business. The opportunity-cost discipline is sound: management is not chasing acquisitions outside its HSA franchise and is not paying a dividend it cannot afford. The risk is the opposite: the company may be buying back stock at a price that already discounts a lot of compounding.

Warren Buffett Lens

The Buffett-style owner-earnings proxy here is operating cash flow minus total capital expenditure, which on a trailing-twelve-month basis is approximately $487.7 million. Calling that "owner earnings" requires flagging two limits: the filings do not separate maintenance from growth capex, and stock-based compensation, while non-cash, is a real dilution cost of about $81.3 million TTM that a buyer must underwrite. On the available numbers, the bridge from free cash flow to equity value is: enterprise value roughly $8.49 billion minus net debt of $0.675 billion equals equity value of about $7.81 billion, almost identical to the dated $7.812 billion market capitalization. That is the cleanest expression of the price: the market is paying roughly the full enterprise-value load for a stream that grows HSA Assets and earns custodial spreads. Buffett would be more interested if the share price were 20% to 30% below this level, where the margin of safety would start to compensate for the regulatory and rate risks that sit inside the HSA franchise.

Charlie Munger Lens

The Munger check is about incentives, inversion and bias. The incentive design is reasonably aligned: heavy stock-based compensation of $81.3 million TTM tied to share price, plus a buyback program that benefits long-term holders when executed below intrinsic value. The inversion question is what breaks the thesis. The most likely break is a sustained decline in short-term interest rates that compresses the custodial spread on $37.9 billion of HSA Assets, which is the single largest revenue line; a 100-basis-point decline in yield would meaningfully compress custodial revenue, and the company uses derivatives to hedge only a portion of that exposure. The second break is regulatory: HSA tax-advantaged status is the foundation of the model, and any narrowing of the triple-tax benefit would shrink both the addressable market and the per-account balance. The bias to watch is enthusiasm about "non-bank financial" growth narratives; the underlying economics are still a function of regulated tax-advantaged accounts and partner-driven deposit rates, not pure software economics.

Li Lu Lens

The Li Lu lens is circle of competence, culture, durability and permanent-loss control. The business is squarely inside a regulated, tax-advantaged structure with clear demand drivers: high-deductible health-plan enrollment, employer adoption of consumer-directed benefits, and a captive float base of $37.9 billion of HSA Assets. Culture is observable through the reported 20% market share gain since 2010 and the 17.8 million accounts administered, which are externally verifiable customer-side metrics, not slogans. Durability is supported by the qualification barrier to become an IRS-approved non-bank custodian, the 200-plus Network Partner integrations, and the recurring revenue mix. The permanent-loss question is whether a regulatory change could destroy the franchise; that risk is real but not imminent. Within the circle of competence, the dated price does not offer a margin of safety, which is the main reason this is a watchlist candidate rather than a buy.

Risks, Disconfirming Evidence, and What Would Prove This Thesis Wrong

The first thesis breaker is a sustained drop in short-term interest rates that compresses the custodial spread on $37.9 billion of HSA Assets, which is the single most exposed revenue line; observable indicators would be Fed Funds moves below current levels and a falling yield on the company's cash and cash equivalents. The second thesis breaker is any federal legislative or regulatory change that narrows the HSA triple-tax-advantaged status, which would shrink both new account growth and the HSA Asset base over time. The third thesis breaker is operational: the company is subject to a consolidated putative class action and regulatory inquiries arising from a fiscal 2025 cybersecurity incident at a business partner, with an unestimable potential loss that could exceed what the filings disclose. Two weaker disconfirming data points are also visible: TTM operating cash flow grew only 0.2% year over year, so the headline revenue growth is not yet flowing through to materially higher cash earnings, and revenue growth of 7.6% in the quarter is the lowest in the trailing periods shown, which could indicate deceleration. If custodial revenue per dollar of HSA Assets falls materially, or if the cybersecurity litigation produces a quantified loss, the conservative conclusion would shift toward avoidance until better evidence emerges.

Investment Conclusion

The dated market capitalization of $7.812 billion at $93.44 per share on August 27, 2026 sits close to the base-scenario output of the deterministic calculation, which permits but does not require a fairly-valued label. The fundamental picture is attractive in shape, with low capital intensity, high cash conversion and disciplined buybacks, but the dated free-cash-flow yield of roughly 6.2% and the embedded growth assumption of about 3.2% leave limited cushion against a rate decline or regulatory shock. The honest verdict is that this is a high-quality compounder trading near fair value, suitable for a watchlist at the dated price rather than an immediate position, and only re-rated attractive if the share price falls into a range that genuinely discounts permanent-loss risk.

---

*This article is for educational and informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All figures derive from publicly filed SEC documents and the dated market snapshot cited above, and any forward-looking statement reflects author assumption rather than company guidance. Past performance is not indicative of future results.*